In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon (original) (raw)

Abstract

The (NZB X NZW)F1 mouse is recognized as an important animal model of the human disease systemic lupus erythematosus (SLE). Groups of NZB/W F1 mice were treated either with IFN-gamma or with PBS. The results demonstrate that IFN-treated animals have accelerated development of fatal immune complex glomerulonephritis relative to age-matched controls. On the other hand, administration of mAbs specific for IFN- gamma to such mice from 4 to 7 mo of age resulted in significant remission. Development of both proteinuria and anti-DNA antibodies were delayed and survival at 11 mo was increased from less than 20% to 95% in treated mice relative to controls (p less than or equal to 0.001). These findings may have therapeutic implications for the treatment of SLE.

Full Text

The Full Text of this article is available as a PDF (391.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adelman N. E., Watling D. L., McDevitt H. O. Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies. J Exp Med. 1983 Oct 1;158(4):1350–1355. doi: 10.1084/jem.158.4.1350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Basham T., Smith W., Lanier L., Morhenn V., Merigan T. Regulation of expression of class II major histocompatibility antigens on human peripheral blood monocytes and Langerhans cells by interferon. Hum Immunol. 1984 Jun;10(2):83–93. doi: 10.1016/0198-8859(84)90075-2. [DOI] [PubMed] [Google Scholar]
  3. Bottazzo G. F., Pujol-Borrell R., Hanafusa T., Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet. 1983 Nov 12;2(8359):1115–1119. doi: 10.1016/s0140-6736(83)90629-3. [DOI] [PubMed] [Google Scholar]
  4. Bottazzo G. F., Todd I., Mirakian R., Belfiore A., Pujol-Borrell R. Organ-specific autoimmunity: a 1986 overview. Immunol Rev. 1986 Dec;94:137–169. doi: 10.1111/j.1600-065X.1986.tb01168.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Engleman E. G., Sonnenfeld G., Dauphinee M., Greenspan J. S., Talal N., McDevitt H. O., Merigan T. C. Treatment of NZB/NZW F1 hybrid mice with Mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease. Arthritis Rheum. 1981 Nov;24(11):1396–1402. doi: 10.1002/art.1780241110. [DOI] [PubMed] [Google Scholar]
  6. Fontana A., Fierz W., Wekerle H. Astrocytes present myelin basic protein to encephalitogenic T-cell lines. Nature. 1984 Jan 19;307(5948):273–276. doi: 10.1038/307273a0. [DOI] [PubMed] [Google Scholar]
  7. Heremans H., Billiau A., Colombatti A., Hilgers J., de Somer P. Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect Immun. 1978 Sep;21(3):925–930. doi: 10.1128/iai.21.3.925-930.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Izui S., McConahey P. J., Dixon F. J. Increased spontaneous polyclonal activation of B lymphocytes in mice with spontaneous autoimmune disease. J Immunol. 1978 Dec;121(6):2213–2219. [PubMed] [Google Scholar]
  9. King D. P., Jones P. P. Induction of Ia and H-2 antigens on a macrophage cell line by immune interferon. J Immunol. 1983 Jul;131(1):315–318. [PubMed] [Google Scholar]
  10. Knight J. G., Adams D. D. Three genes for lupus nephritis in NZB x NZW mice. J Exp Med. 1978 Jun 1;147(6):1653–1660. doi: 10.1084/jem.147.6.1653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nathan C. F., Kaplan G., Levis W. R., Nusrat A., Witmer M. D., Sherwin S. A., Job C. K., Horowitz C. R., Steinman R. M., Cohn Z. A. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med. 1986 Jul 3;315(1):6–15. doi: 10.1056/NEJM198607033150102. [DOI] [PubMed] [Google Scholar]
  12. Noma Y., Sideras P., Naito T., Bergstedt-Lindquist S., Azuma C., Severinson E., Tanabe T., Kinashi T., Matsuda F., Yaoita Y. Cloning of cDNA encoding the murine IgG1 induction factor by a novel strategy using SP6 promoter. Nature. 1986 Feb 20;319(6055):640–646. doi: 10.1038/319640a0. [DOI] [PubMed] [Google Scholar]
  13. Reinertsen J. L., Klippel J. H., Johnson A. H., Steinberg A. D., Decker J. L., Mann D. L. B-lymphocyte alloantigens associated with systemic lupus erythematosus. N Engl J Med. 1978 Sep 7;299(10):515–518. doi: 10.1056/NEJM197809072991004. [DOI] [PubMed] [Google Scholar]
  14. Sakai K., Tabira T., Endoh M., Steinman L. Ia expression in chronic relapsing experimental allergic encephalomyelitis induced by long-term cultured T cell lines in mice. Lab Invest. 1986 Mar;54(3):345–352. [PubMed] [Google Scholar]
  15. Sergiescu D., Cerutti I., Efthymiou E., Kahan A., Chany C. Adverse effects of interferon treatment on the life span of NZB mice. Biomedicine. 1979 Apr;31(2):48–51. [PubMed] [Google Scholar]
  16. Wong G. H., Clark-Lewis I., McKimm-Breschkin L., Harris A. W., Schrader J. W. Interferon-gamma induces enhanced expression of Ia and H-2 antigens on B lymphoid, macrophage, and myeloid cell lines. J Immunol. 1983 Aug;131(2):788–793. [PubMed] [Google Scholar]
  17. Zouali M., Stollar B. D. A rapid ELISA for measurement of antibodies to nucleic acid antigens using UV-treated polystyrene microplates. J Immunol Methods. 1986 Jun 10;90(1):105–110. doi: 10.1016/0022-1759(86)90390-x. [DOI] [PubMed] [Google Scholar]
  18. van der Meide P. H., Dubbeld M., Vijverberg K., Kos T., Schellekens H. The purification and characterization of rat gamma interferon by use of two monoclonal antibodies. J Gen Virol. 1986 Jun;67(Pt 6):1059–1071. doi: 10.1099/0022-1317-67-6-1059. [DOI] [PubMed] [Google Scholar]